Browse News
Filter News
Found 793,877 articles
-
Johnson & Johnson’s AI investments include a research facility in San Francisco and a data science workforce of approximately 6,000 employees.
-
Moving RNA Therapeutics Beyond the Liver
12/4/2023
From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain. -
For forms of Alzheimer’s, frontotemporal dementia and Parkinson’s caused by genetic defects, gene therapy could change the treatment landscape.
-
This week, the FDA could approve the first CRISPR-edited therapy in the U.S., while two other companies await decisions on topical drugs.
-
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
12/4/2023
Everest Medicines announced that China National Medical Products Administration has accepted its investigational new drug application for zetomipzomib in China.
-
Chimerix Promotes Michelle LaSpaluto to Chief Financial OfficerProven Leader Brings More Than 25 Years of Financial Experience
12/4/2023
Chimerix today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023.
-
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
12/4/2023
Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.
-
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
12/4/2023
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced a successful end-of-Phase 2 Meeting with the U.S. Food & Drug Administration (FDA), supporting the advancement of pegozafermin into Phase 3 in NASH.
-
Aurora Spine Corporation Announces Newly Published Paper on First 6-month Clinical Evaluation of its ZIP™ Fusion Implant
12/4/2023
Aurora Spine Corporation today announced the publication of the first 6-month clinical evaluation of its ZIP™ fusion implant in the Journal of Pain Research.
-
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
12/4/2023
TScan Therapeutics, Inc. today announced the appointment of Justin McCue, Ph.D., as its Chief Technology Officer.
-
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitTop-line Efficacy and Safety Data on Track for Release in December 2023
12/4/2023
OKYO Pharma Limited is pleased to announce the last patient of a planned 240-patient double-blind placebo-controlled phase 2 clinical trial of OK-101 to treat DED has completed the 12-week OK-101 dosing study.
-
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
12/4/2023
Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.
-
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
12/4/2023
Apollomics Inc. today announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC), that was held December 1-3, 2023, in Chicago, Illinois.
-
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints
12/4/2023
EyePoint Pharmaceuticals, Inc. today announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™.
-
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
12/4/2023
Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support clinical development of TNX-2900 (intranasal potentiated oxytocin), a proprietary magnesium (Mg2+)-enhanced formulation of intranasal oxytocin, to treat Prader-Willi syndrome (PWS) in children and adolescents.
-
Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board
12/4/2023
Nanoscope Therapeutics today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately.
-
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
12/4/2023
RedHill Biopharma Ltd. today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment.
-
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
12/4/2023
Alterity Therapeutics today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate model was presented at the Future of Parkinson’s Disease Conference 2023 that took place November 30 – December 3, 2023 in Austin, TX, USA.
-
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
12/4/2023
Atsena Therapeutics today announced positive 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).
-
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
12/4/2023
Geron Corporation announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes relapsed/refractory or ineligible for erythropoiesis stimulating agents.